These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27907034)

  • 1. Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil.
    Laranjeira FO; Silva EN; Pereira MG
    PLoS One; 2016; 11(12):e0167039. PubMed ID: 27907034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
    Gundgaard J; Christensen TE; Thomsen TL
    Prim Care Diabetes; 2010 Oct; 4(3):165-72. PubMed ID: 20452847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.
    Caires de Souza AL; de Assis Acurcio F; Guerra Júnior AA; Rezende Macedo do Nascimento RC; Godman B; Diniz LM
    Appl Health Econ Health Policy; 2014 Feb; 12(1):19-32. PubMed ID: 24385261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
    J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
    Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
    J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus.
    Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
    Am J Manag Care; 2015 Mar; 21(3):e235-43. PubMed ID: 26014311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.
    Jendle J; Ridderstråle M; Torfvitt O; Ericsson A; Larsen S
    J Med Econ; 2012; 15(2):261-3. PubMed ID: 22142237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
    Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
    Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.
    Lee TY; Kuo S; Yang CY; Ou HT
    Br J Clin Pharmacol; 2020 May; 86(5):852-860. PubMed ID: 31782975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the use and cost of human and analogue insulins in a Colombian population, 2011-2015.
    Torres DR; Portilla A; Machado-Duque ME; Machado-Alba JE
    Public Health; 2017 Dec; 153():64-69. PubMed ID: 28950114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of paediatric diabetes care in Germany: current situation and comparison with the year 2000.
    Bächle CC; Holl RW; Straßburger K; Molz E; Chernyak N; Beyer P; Schimmel U; Rütschle H; Seidel J; Lepler R; Holder M; Rosenbauer J; Icks A; ;
    Diabet Med; 2012 Oct; 29(10):1327-34. PubMed ID: 22417295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.
    Rossetti P; Ampudia-Blasco FJ; Ascaso JF
    Diabetes Obes Metab; 2014 Aug; 16(8):695-706. PubMed ID: 24401118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
    Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
    Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.